Nicole Grunenberg
Overview
Explore the profile of Nicole Grunenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Alam S, Andersen-Nissen E, Carpp L, Dintwe O, Flach B, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339842
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An...
2.
Naicker V, Laher F, Bekker L, Seaton K, Allen M, De Rosa S, et al.
PLOS Glob Public Health
. 2024 Sep;
4(9):e0003319.
PMID: 39302924
Induction of broad, durable immune responses is a challenge in HIV vaccine development. HVTN 100 Part A administered subtype C-containing ALVAC-HIV at months 0 and 1, and ALVAC-HIV with bivalent...
3.
Garrett N, Dintwe O, Monaco C, Jones M, Seaton K, Church E, et al.
J Acquir Immune Defic Syndr
. 2024 Jun;
96(4):350-360.
PMID: 38916429
Background: An effective vaccine is required to end the HIV pandemic. We evaluated the safety and immunogenicity of a DNA (DNA-HIV-PT123) vaccine with low- or high-dose bivalent (TV1.C and 1086.C...
4.
Chihana R, Kee J, Moodie Z, Huang Y, Janes H, Dadabhai S, et al.
Vaccine
. 2024 May;
42(20):125991.
PMID: 38772835
Background: Reactogenicity informs vaccine safety, and may influence vaccine uptake. We evaluated factors associated with reactogenicity in HVTN 702, a typical HIV vaccine efficacy trial with multiple doses and products....
5.
Frank I, Li S, Grunenberg N, Overton E, Robinson S, Zheng H, et al.
Lancet HIV
. 2024 May;
11(5):e285-e299.
PMID: 38692824
Background: An effective HIV vaccine will most likely need to have potent immunogenicity and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 was to evaluate...
6.
Erdmann N, Williams W, Walsh S, Grunenberg N, Edlefsen P, Goepfert P, et al.
medRxiv
. 2024 Apr;
PMID: 38562833
Background: HIV-1 vaccine development is a global health priority. Broadly neutralizing antibodies (bnAbs) which target the HIV-1 gp41 membrane-proximal external region (MPER) have some of the highest neutralization breadth. An...
7.
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe O, Laher Omar F, Kee J, et al.
PLoS Med
. 2024 Mar;
21(3):e1004360.
PMID: 38502656
Background: Adjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the...
8.
Miner M, deCamp A, Grunenberg N, De Rosa S, Fiore-Gartland A, Bar K, et al.
EBioMedicine
. 2024 Feb;
100:104987.
PMID: 38306894
Background: Elicitation of broad immune responses is understood to be required for an efficacious preventative HIV vaccine. This Phase 1 randomized controlled trial evaluated whether administration of vaccine antigens separated...
9.
Stephenson K, Marcelin J, Pettifor A, Janes H, Brown E, Neradilek M, et al.
Open Forum Infect Dis
. 2023 Nov;
10(11):ofad511.
PMID: 38023544
Background: The efficacy of messenger RNA (mRNA)-1273 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not well defined, particularly among young adults. Methods: Adults aged 18-29 years with...
10.
Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M, et al.
EClinicalMedicine
. 2023 Nov;
64:102168.
PMID: 37936652
Background: The literature on first generation COVID-19 vaccines show they were less effective against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and BA.5 subvariants). New vaccines developed...